MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma

Follicular Lymphoma and Marginal Zone Lymphoma Clinical Trial

Official title: A Multi-center, Open Label, Phase III Study to Evaluate the Efficacy and Safety of MIL62 Plus Lenalidomide Versus Lenalidomide in Subjects With Follicular Lymphoma Refractory to Rituximab

Status Recruiting

Clinical Trial Summary

This phase III trial aims to compare the efficacy and safety of MIL62 combined lenalidomide and lenalidomide alone to treat patient diagnosed with Follicular Lymphoma (FL) and refractory to rituximab. The study randomized patients with a 1:1 ratio to receive either MIL62 plus lenalidomide or lenalidomide.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Follicular Lymphoma and Marginal Zone Lymphoma
• Lymphoma
• Lymphoma, B-Cell, Marginal Zone
• Lymphoma, Follicular

• NCT number: NCT04834024
• Study type: Interventional
• Source: Beijing Mabworks Biotech Co., Ltd.
• Contact: Yuankai Shi, doctor
• Phone: 8610-87788293
• Email: syuankaipumc@126.com
• Status: Recruiting
• Phase: Phase 3
• Start date: June 2, 2021
• Completion date: March 2025